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12 ABSTRACT Pulmonary vaccine delivery has gained significant
13 attention as an alternate route for vaccination without the use of
14 needles. Immunization through the pulmonary route induces
15 both mucosal and systemic immunity, and the delivery of anti-
16 gens in a dry powder state can overcome some challenges such
17 as cold-chain and availability of medical personnel compared to
18 traditional liquid-based vaccines. Antigens formulated as nano-
19 particles (NPs) reach the respiratory airways of the lungs pro-
20 viding greater chance of uptake by relevant immune cells. In
21 addition, effective targeting of antigens to the most ‘professional’
22 antigen presenting cells (APCs), the dendritic cells (DCs) yields
23 an enhanced immune response and the use of an adjuvant
24 further augments the generated immune response thus requir-
25 ing less antigen/dosage to achieve vaccination. This review
26 discusses the pulmonary delivery of vaccines, methods of pre-
27 paring NPs for antigen delivery and targeting, the importance of
28 targeting DCs and different techniques involved in formulating
29 dry powders suitable for inhalation.
30 KEY WORDS antigen presenting cells . dendritic cells .
31 dry powder . polymeric nanoparticles . pulmonary delivery of
32 vaccines
33ABBREVIATIONS
35AMs 6Alveolar macrophages
37APCs 8Antigen presenting cells
39BAL 40Bronchoalveolar lavage
41CLRs 2C-type lectin receptors
43DCs 4Dendritic cells
45DPI 6Dry powder inhalations
47FD 8Freeze-drying
49HLA 50Human leukocyte antigen
51ILs 2Interleukins
53LN 4Lymph node
55MHC 6Major histocompatibility complex
57MN 8Mannan
59NPs 60Nanoparticles
61PCL 2Poly-ε-caprolactone
63PEG 4Polyethylene glycol
65PEI 6Polyethyleneimine
67PLA 8Polylactide or poly-L-lactic acid
69PLGA 70Poly lactic-co-glycolic-acid
71PRRs 2Pattern recognition receptors
73PVA 4Polyvinyl alcohol
75SCF 6Supercritical fluid
77SD 8Spray-drying
79SFD 80Spray-freeze drying
81TLRs 2Toll-like receptors
83TMC 4N-Trimethyl chitosan
85VLPs 6Virus-like particles
87
88INTRODUCTION
89New therapeutic biopharmaceuticals have made it possible
90to treat and/or prevent many diseases which were untreat-
91able a decade ago (1). The majority of these biopharma-
92ceuticals are administered via parenteral routes because
93they are degraded by acid and proteases in the stomach or
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94 have high first-pass metabolism and as such are not suitable
95 for oral delivery. The formulation of biopharmaceuticals in
96 non-invasive delivery systems in order to make them more
97 acceptable to patients has gained significant attention but the
98 pharmaceutical challenges are stability, integrity and effective-
99 ness within the therapeutic dose (1,2). The leading non-
100 invasive systems are buccal, nasal, pulmonary, sublingual
101 and transdermal routes—this review will focus on the pulmo-
102 nary route and on vaccine delivery in particular.
103 Pulmonary delivery of vaccines has gained major atten-
104 tion for achieving both mucosal and systemic immunity (3).
105 An optimum formulation containing antigens in the dry
106 state as nanoparticles (NPs) can result in greater stability
107 and a better immune response compared to traditional
108 liquid-based vaccines (3). NPs as colloidal carriers offer
109 protection of biopharmaceuticals against degradation, and
110 targeted delivery to specific sites of action. NPs can be
111 developed with variable physico-chemical characteristics
112 such as size, structure, morphology, surface texture and
113 composition, and thus can be delivered either orally, paren-
114 terally or locally (4).
115 This review discusses the pulmonary delivery of vaccines,
116 methods of preparing NPs, the importance of targeting den-
117 dritic cells (DCs) (antigen presenting cells-APCs) and different
118 techniques involved in making dry powders suitable for inha-
119 lation. Progress in the delivery of biopharmaceuticals via
120 buccal (5–7), nasal (8), sublingual (9) and transdermal (10)
121 routes has previously been reported elsewhere and is beyond
122 the scope of this review.
123 Since the term ‘vaccination’ was coined by Edward
124 Jenner in 1796, it has been arguably the most important
125 scientific advance in the battle against infectious disease (11).
126 According to the World Health Organization (WHO),
127 around 2.5 million children’s lives are saved each year due
128 to the availability of vaccines against a variety of antigens
129 (12). However, in low and middle income countries (LMIC)
130 a lack of infrastructure such as cold-chain and trained med-
131 ical personnel essential for the administration of traditional
132 liquid-based vaccine formulations, means that many eligible
133 children and adults are not vaccinated (12). Table I below
134 provides a list of reported cases by disease according to
135 World Health Statistics (WHS) 2011 (13). Hence, there is
136 a global need to develop effective and reliable vaccine
137 strategies that are non-invasive, easily accessible and afford-
138 able (14). To address the issues with liquid-based vaccine
139 formulations in LMIC, non-invasive routes of delivery,
140 which do not have the requirements of cold-chain or trained
141 personal are being investigated (3).
142 Of all the non-invasive routes of delivery, pulmonary
143 delivery can overcome some of the current challenges of
144 vaccination such as invasiveness, accessibility, and vaccine
145 stability and integrity by delivering vaccines as dry powder
146 inhalations (DPI) (14). In addition, the pulmonary route has
147gained much attention as it is the main entry portal for
148pathogens (2,15).
149PULMONARY VACCINE DELIVERY
150Pulmonary delivery as a route of drug administration can be
151traced back 4000 years to India where people suffering from
152cough suppressed it by inhaling the leaves of Atropa Belladon-
153na (16). Later in the 19th and 20th centuries, people suffer-
154ing from asthma smoked cigarettes containing tobacco and
155stramonium powder to alleviate their symptoms (16). The
156first inhaling apparatus for dry powder delivery was patent-
157ed in London in 1864 (17). Since then much progress has
158been made in developing devices such as nebulizers,
159metered dose inhalers and DPIs for delivery of therapeutics.
160With recent advancements in pulmonary delivery devices
161and recombinant protein technology the first peptide DPI
162formulation, Exubera (Nektar/Pfizer), was approved and
163released into the market in January 2006. This was soon
164withdrawn for several reasons including bulkiness of the
165device, complicated administration, contraindication in
166smokers and insufficient evidence with regulatory bodies
167regarding the patients preference of Exubera (inhaled dosage
168form) compared to other dosage forms (18). This led, however,
169to further research and development of DPI of biopharma-
170ceuticals, and currently many investigations are being pursued
171by the pharmaceutical industry such as the AIR system
172(Alkermes/Eli Lilly), the Technosphere system (Mannkind)
173and Kos inhaled insulin (Kos Pharm/Abbott) for Type I/II
174diabetes, and Granulocyte-colony-stimulating factor (G-CSF)
175for Neutropenia (Amgen) (19). This has been followed by
176investigations into DPI of vaccines (20–24).
177Anatomy of the Human Lung
178The human lung, weighing about 1 kg, is divided by the
179pleural membranes into three lobes on the right and two
t1:1Table I List of Reported Cases by Disease According to World Health
Statistics (WHS) 2011
t1:2Disease Reported Cases (WHS 2011)a
t1:3Diptheria 857
t1:4Malaria 81,735,305 (1990–2009)
t1:5Measles 222,318
t1:6Mumps 546,684
t1:7Tetanus 9,836
t1:8Tuberculosis 5,797,317
t1:9Pneumonia (Children <5 years) ~1,400,000 (18% of all child
deaths in 2008) (120)
a Data provided not necessarily for the year 2011, more details at http://
www.who.int/whosis/whostat/2011/en/index.html
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180 lobes on the left (25). Once inhaled, the air passes through
181 the nose and mouth, from the larynx to trachea and to the
182 series of around 16 generations of conductive bronchi and
183 bronchioles (25,26). From the 17th generation of bron-
184 chioles, alveoli begin to appear in the walls (respiratory
185 airways) and by the 20th generation of airways, the entire
186 walls are composed of alveoli, commonly referred to as
187 alveolar ducts. At the 23rd generation, the alveolar
188 ducts end in blind sacs, lined with alveoli, and are referred
189 to as alveolar sacs (Fig. 1) (25–27). It is estimated that
190 on an average a human lung consists of about 300 million
191 alveoli providing a surface area of exchange of 80–90 sq. m
192 (25,28).
193 The submucosal glands and the ‘goblet cells’ (present on
194 the bronchial surface) secrete mucus onto the bronchial sur-
195 faces. The submucosal glands also help in producing an elec-
196 trolyte solution on which the mucus rests. Themucus covering
197 the airways is transported towards the mouth with the coor-
198 dinated movement of cilia present on top of the ciliated
199 columnar cells. This mucus transported to the mouth is then
200 swallowed. This process of mucus movement from the bron-
201 chial surfaces to the mouth for swallowing is mainly responsi-
202 ble for removing any foreign material that lands on the
203 bronchial surfaces (25).
204 The alveoli and the pulmonary capillaries are separated by
205 a barrier composing of endothelial cells, interstitial space, and
206 pneumocytes (pulmonary epithelial cells). The pneumocytes
207are divided into two types, type I and type II cells. Type I are
208very flat and cover the alveolar surface whereas type II are
209irregularly shaped containing lamellar bodies that are secreted
210as surfactant, and they can further divide and produce type I
211and type II cells (25).
212Lung as a Delivery Site for Drugs
213The lung is an excellent choice for the delivery of biophar-
214maceuticals for the treatment of both local and systemic
215disorders as it offers several advantages such as; large surface
216area (80 sq. m), dense vasculature, rapid absorption leading
217to an immediate onset of action, thin alveolar epithelium,
218less enzymatic activity than gut and a high capacity for
219solute exchange (29). With regards to the delivery of vac-
220cines, a high density of APCs including alveolar macro-
221phages (AMs), DCs and B cells represent an ideal target to
222induce a strong immune response resulting in both mucosal
223and systemic immunity (14). Recent research has con-
224firmed that the induction of an immune response at one
225mucosal site elicits an immune response at distant muco-
226sal sites by mucosal lymphocyte trafficking leading to
227both mucosal and systemic immunization (15,30). There
228is some evidence that mucosal immunization may also
229reduce the dosage required to achieve the desired immunity
230compared to liquid formulations administered via the
231parenteral route (3).
Fig. 1 Diagram of the human
lung and particle deposition
based on size.
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232 Pulmonary vs Parenteral Vaccine Delivery
233 In development of novel anti-tuberculosis vaccines, Ballester
234 M et al. demonstrated, that inhaled vaccine compared fa-
235 vorably to an intradermal route of delivery. In particular,
236 vaccination with NP-Ag85B and immune-stimulatory oligo-
237 nucleotide CpG as a Th1-promoting adjuvant via the pul-
238 monary route modified the pulmonary immune response
239 and provided significant protection following aMycobacterium
240 tuberculosis (Mtb) aerosol challenge (31).
241 Muttil P et al. successfully prepared poly lactic-co-
242 glycolic-acid (PLGA) NPs entrapping diphtheria CRM-197
243 antigen (CrmAg) with a size of 200±50 nm by the emulsi-
244 fication solvent diffusion and double-emulsion methods.
245 The NPs were then spray-dried with L-leucine and the
246 resulting spray-dried powders of formalin-treated/untreated
247 CrmAg nanoaggregates were delivered to the lungs of guin-
248 ea pigs. This study evaluated the immune response elicited
249 in guinea pigs following pulmonary and parenteral immu-
250 nizations with the dry powders and the highest titer of serum
251 IgG antibody was observed in guinea pigs immunized by the
252 intramuscular route whereas high IgA titers were observed
253 for dry powder formulations administered by the pulmonary
254 route. This demonstrates that pulmonary immunization
255 with dry powder vaccines leads to a high mucosal immune
256 response in the respiratory tract and sufficient neutralizing
257 antibodies in the systemic circulation to provide protection
258 against diphtheria (32).
259 An ideal vaccine formulation for mass vaccination would
260 induce the desired immunity upon administration of a single
261 dose. Moreover, it is important to target APCs like DCs to
262 illicit a strong and durable immune response with a single dose
263 aimed at both systemic and mucosal immunity (33).
264 Dendritic Cells
265 Dendritic cells (DCs) were first identified in 1868 by Paul
266 Langerhans in the basal layer of the epidermis (34). How-
267 ever, it took more than a century to properly identify them
268 as white blood cells related to macrophages and monocytes,
269 and to understand their importance in the control of immu-
270 nity (34,35). In 2011, the Nobel Prize in Physiology or
271 Medicine was awarded to Ralph M. Steinman for his dis-
272 covery of DCs and their role in adaptive immunity paving
273 the way for more research in the field of immunity and
274 vaccines (36). It has become evident over the years that
275 DCs are APCs, true ‘professionals’ (37) with exceptional
276 capability to internalize, process and present antigens
277 through major histocompatibility complex (MHC) class I
278 and II pathways. DCs induce a strong immune response
279 by activating naïve T-cells which are produced in the bone
280 marrow and have the capability to respond to novel patho-
281 gens that have not been processed before (38,39). The role
282of DCs in initiating a primary immune response has now
283been shown to be greater than the role played by macro-
284phages and the B-cells (40).
285The lung is armed with an intricate network of DCs that
286can be found throughout the conducting airways, lung
287interstitium, lung vasculature, pleura, and bronchial lymph
288nodes (41,42). It is now apparent that there are at least five
289different subsets of DCs in the murine lung; resident DCs,
290plasmacytoid DCs, alveolar DCs, inflammatory DCs and
291interferon-producing killer DCs (41,42). The data for the
292subsets of DCs in the human lung is rare (43) owing to the
293need to obtain lung tissue, as they are not found in the
294bronchoalveolar lavage (BAL) fluid. However, studies on
295the human AMs are common as they are readily obtained
296from BAL (44). The AMs are primarily phagocytes with
297poor APC function and live in the air space, whereas im-
298mature DCs have high APC function but lower phagocytic
299function and live mainly in the interstitium (45). In the
300human lung, the mucosal surface in the conducting airways
301consists of ciliated epithelial cells, interspersed goblet cells,
302macrophages and DCs (46). The DC population in this
303region is mainly composed of myeloid DCs (mDCs), how-
304ever, a fraction of plasmacytoid DCs (pDCs) can be found
305(46). These mDCs have a high capability for antigen uptake
306but less ability to stimulate the T cells (46). Moreover, the
307human DCs are generated from haematopoietic stem cells,
308mDCs from bone marrow–derived monocytic precursors
309and pDCs from lymphoid progenitors (34). The mDCs
310and pDCs are activated by a different set of pathogenic
311stimuli making them functionally distinct reflected by the
312different expression of cell surface receptors such as Toll-like
313receptors (TLRs) (34,46). The lung parenchyma consisting
314of lung interstitium, respiratory and terminal bronchioles,
315and alveoli is mainly composed of 80% macrophages with
316rest being DCs and T cells. The ‘immature’ resident DCs
317are highly capable of detecting, capturing and processing
318the encountered antigen (34,46).
319The human DCs are identified by over expression of
320human leukocyte antigen (HLA) DR (major histocompati-
321bility complex class II) with the absence of monocyte, lym-
322phocyte, natural killer cell and granulocyte lineage markers
323(43). In addition, the specific markers for identifying the
324mDCs include CD11c+, CD1a+, BDCA-1+, BDCA-3+,
325HLA-DR+ whereas for the pDCs they are CD11c−, HLA-
326DR+, BDCA-2+ and CD123+ (43,46,47).
327Inhaled antigens or antigen particulates are believed to
328encounter the wide spread DC network that lines the alve-
329olar epithelium and are subsequently taken up by cellular
330processes extending in to the alveolar lining fluid (33). Anti-
331gens are then processed and fragments of antigenic peptides
332are presented on the surface through MHC class I and II
333pathways for recognition by the T-cell receptors present on
334T-cells (40). This process is often referred to as antigen
Kunda et al.
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335 presentation and typically takes place in the regional lymph
336 node after chemokine dependent migration of the antigen
337 loaded DC. Also, APCs perceive danger signals from cells
338 and offer co-stimulatory signals (48) through co-stimulatory
339 molecules present on their surface for recognition by recep-
340 tors on recirculating T-cells to initiate an immune response
341 in the lymph node (40). Upon encountering the danger
342 signals, immature DCs change to a mature stage where they
343 present the antigen on their surface. This step is usually
344 concurrent with the migration of DCs from peripheral tissue
345 to the lymph node for T-cell activation (Fig. 2). It is believed
346 that soon after antigen presentation, the DCs undergo apo-
347 ptosis in the lymph nodes (40).
348Antigen uptake by DCs occurs by macro-pinocytosis,
349receptor-mediated endocytosis (macrophage mannose recep-
350tor) and/or phagocytosis (49–52). Recent research by Foged et
351al. has shown that both particle size and surface charge of the
352material to be delivered plays an important role in determining
353the uptake by human DCs derived from blood. Furthermore, it
354was recognised that for optimal uptake by DCs the preferred
355particle size was 0.5 μm (diameter). Uptake of large particles
356(~ 1 μm) was greatly enhanced when they displayed a positive
357surface charge (53). In addition, a study conducted by Mano-
358lova et al. revealed that upon intracutaneous injection of poly-
359styrene beads of varying sizes the large particles (500–2000 nm)
360associated with DCs from the site of injection and depended
Fig. 2 Antigen uptake and
presentation by dendritic cells
(DCs) in the airways. 1 a Upon
exposure of an inhaled antigen the
immature DCs migrate towards
the site of attack. DCs at this stage
express a wide variety of receptors
(Fc, C-type lectin receptors etc.)
and uptake the antigen. Simulta-
neously, some DCs upregulate the
CC-chemokine receptor 7
(CCR7) and migrate towards the
lymphatic vessels expressing CC-
chemokine ligand 21 (CCL-21)
where they are carried to the
draining lymph node. After antigen
uptake and activation, high
amounts of peptide-loaded major
histocompatibility complex (MHC)
molecules and T-cell
co-stimulatory receptors appear
on the surface of DCs. The DCs
then migrate to the lymph nodes
and activate the antigen specific
T-cells. 1 b After antigen uptake,
the antigen is either processed
through MHC class I (either
through endogenous or exoge-
nous pathway) orMHC class II (the
antigen is degraded in endosomes
and the obtained polypeptide is
transported and loaded onto
MHC II molecules) and DCs
present it on their surface for
specific T-cell activation. *ER – En-
doplasmic reticulum.
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361 largely on them for cellular transport, whereas small particles
362 (20–200 nm) and virus-like particles (VLPs) (30 nm) drained
363 freely to the lymph nodes (LNs) and were present in LN-
364 resident DCs and macrophages (54). However, this cannot be
365 directly compared to pulmonary delivery as theDCs in the lung
366 differ from those of the skin.
367 Targeting Antigen to the DC
368 Antigen can be targeted to DCs, for enhanced immune re-
369 sponse, by making particles that bind to the specific receptors
370 expressed on the DC surface (49–51). Effective targeting of
371 vaccines to the DCs results in the possibility of a reduced
372 vaccine dose, less side effects, improved efficacy and enhanced
373 immune response (40).
374 Vaccines can be targeted to DCs in different ways (40,
375 55–57). DCs contain pattern recognition receptors (PRRs)
376 that aid in detecting the presence of a pathogen through
377 interaction with pathogen-associated molecular patterns.
378 More specifically, C-type lectin receptors (CLRs), a type of
379 PRR, bind to sugar moieties (e.g., mannose, glucan) in a
380 calcium-dependent manner present on the pathogen’s sur-
381 face. This leads to antigen internalization through receptor
382 mediated endocytosis resulting in antigen presentation to T-
383 cells (58,59). Vaccines can also be targeted to DCs with anti-
384 bodies having an affinity towards specific receptors present on
385 their surface (e.g. anti-DEC205, anti-CD11c), internalization
386 through phagocytosis and conjugation of danger signals that
387 effectively bind to Toll-like receptors (TLRs) or cytokine
388 receptors thereby inducing DC maturation (40,55). Table II
389 lists some formulations that have been effectively targeted to
390 DCs for an enhanced immune response. There are currently
391no publications that establish targeting of pulmonary DCs
392through pulmonary delivery of dry powder vaccines.
393Nanoparticles for Inhalation
394Generally nanoparticles (NPs) are referred to as particles in the
395size range of 1—100 nm, however for drug delivery NPs larger
396than 100 nm are required for efficient drug loading, and have
397been in use for the last 40 years (60). NPs are used as drug
398carriers either by encapsulating, dissolving, surface adsorbing
399or chemically attaching the active substance (60). NPs have a
400large surface area-to-volume ratio and also an increased satu-
401ration solubility thus favoring application in the field of drug
402delivery. In delivery of NPs to the lung by inhalation, deposition
403takes place through impaction, sedimentation, interception or
404diffusion (Table III) depending on particle size, density, airflow,
405breathing rate, respiratory volume and the health of the indi-
406vidual (61,62). These are discussed in greater detail by Smyth
407HDC et al. (63) and definitions are summarized in Table III.
408The deposition of particles in the lungs is evaluated using the
409aerodynamic particle size, which is defined as the diameter of a
410sphere (density-1 g/cm3) in air that has the same velocity as the
411particle in consideration (60). This is defined by the equation
da ¼ dg
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ρ ρa=
p
4123where ρ is the mass density of the particle, ρa is the unit density
414(1 g/cm3) and dg is the geometric diameter.
415Particles greater than 10 μm (da) in size are commonly
416impacted in the throat or sedimented in the bronchial
417region whereas particles less than 1 μm (da) in size are
418exhaled and not likely to be deposited in the alveolar region.
419It is expected that particles in the size range of 1 to 5 μm (da)
t2:1 Table II Examples of Formulations Targeting Dendritic Cells (DCs)
t2:2 Formulation Target Model drug Model Ref
t2:3 Polyanhydride NPs with dimannose Mannose receptor CD206 NA In vitro (58)
t2:4 MN-decorated PLGA NPs Mannose receptor CD206 NA In vitro (121)
t2:5 PLGA NPs DEC-205 receptor Ovalbumin Mice (122)
t2:6 PLGA NPs Humanized targeting antibody hD1 (DC-SIGN) FITC-TT/DQ Green BSA In vitro (123)
t2:7 PLGA NPs coated with streptavidin gp120, ManLAM, Lex, aDC-SIGN 1,
aDC-SIGN 2, aDC-SIGN 3
DQ-BSA, gp100272-300
and FITC-TT
In vitro (56)
t2:8 Carbon magnetic NPs (CMNPs) Endocytosis Hen egg lysozyme (HEL) Mice (124)
t2:9 Polystyrene and PLGA microparticles CD40, Fcg, α(v)β3 and α(v)β5 NA In vitro (125)
t2:10 Acid degradable particles DEC-205 receptor Ovalbumin Mice (124)
t2:11 PAMAM dendrimer Mannose receptor CD206 Ovalbumin Mice (126)
t2:12 Liposome (with tri-mannose)
(L-Phosphatidylcholine + M3-DPPE)
Mannose receptor CD206 FITC-Ovalbumin In vitro (127)
t2:13 Niosomes (coated with polysaccharide
o-palmitoyl MN)
Mannose receptor CD206 TT Albino Rats (128)
M3- DPPE trimannose-dipalmitoylphosphatidylethanolamine, ManLAM Mannosylated lipoarabinomannan, MN Mannan, Niosomes Sorbiton Span 60,
cholesterol, stearylamine, PAMAM Polyamidoamine, PLGA poly lactic-co-glycolic-acid, TT Tetanus Toxoid, NA Not Applicable
Kunda et al.
JrnlID 11095_ArtID 891_Proof# 1 - 21/09/2012
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
420 avoid deposition in the throat and reach the respirable airways
421 (Fig. 1) and the periphery of the lung (61). Particles less than
422 1 μm (referred to as NPs) are driven by diffusion and are most
423 likely to be exhaled, hence they are therefore often delivered
424 within microparticles. In addition, upon long term storage
425 NPs tend to aggregate due to high particle-particle interac-
426 tions (60). Microparticles prepared from NPs are typically
427 about 1–5 μm in size and usually also encompass inert phar-
428 maceutical excipients (sugars, amino acids etc.) that act as
429 carriers. The excipients dissolve upon encountering the respi-
430 ratory environment thereby releasing the NPs.
431 Different types of NPs have been explored for vaccine
432 delivery and antigenic peptides or proteins are either surface
433 adsorbed or encapsulated within the NPs. Table IV outlines
434 some types of NPs evaluated for vaccine delivery.
435 This review focuses on polymer-basedNPs because they have
436 been extensively investigated as vaccine delivery systems due to
437 their enhanced uptake by phagocytic cells, thereby facilitating
438 antigen internalization and presentation in DCs. In addition,
439 both antigen and materials that augment the immune response
440 (adjuvants) can be encompassed together in nanocomposite
441 microparticles, resulting in their simultaneous delivery (64).
442Polymer-based Nanoparticles
443Wide varieties of polymers, both natural and synthetic, have
444been exploited to form biodegradable NPs. In addition, some
445of the polymers can act as adjuvants themselves (65). Natural
446polymers that have been widely investigated for formulating
447NPs include albumin, alginate, chitosan, collagen, cyclodex-
448trin and gelatin; synthetic polymers include polyesters, poly-
449lactides, polyacrylates, polylactones and polyanhydrides
450(66,67). While natural polymers have a relatively short dura-
451tion of drug release, synthetic polymers can be tailored to
452release the drug over days to several weeks allowing the usage
453of a single dose rather than multiple doses (65).
454Biodegradable polymers have gained significant attention
455for the preparation of NPs for drug delivery and are often
456favored as they offer several advantages such as controlled or
457sustained drug release, biocompatibility with the surrounding
458tissues and cells, low toxicity, are nonthrombogenic and are
459more stable in the blood (66,68). Biodegradable polymer-based
460NPs also offer an additional advantage for vaccine delivery
461systems by acting as adjuvants and aiding in activating both
462cellular and humoral immune responses (69). It has been
t3:1 Table III Broad Descriptions of Impaction, Sedimentation, Interception and Diffusion
t3:2 Impaction The delivered particles, due to inertia, do not change their path and as the airflow changes with bifurcations they tend to get impacted on
the airway surface. This is mostly experienced by large particles and is highly dependent on the aerodynamic properties of the particles.
t3:3 Sedimentation The settling down of the delivered particles. This is generally observed in the bronchioles and alveoli.
t3:4 Interception This occurs when particles, due to their shape and size, interact with the airway surface and is experienced when the particles are close to
the airway wall.
t3:5 Diffusion Is the transport of particles from a region of higher concentration to lower concentration, is observed for particles that are less than 0.5 μm in
diameter and occurs in the regions where the airflow is low. This is highly dependent on the geometric diameter of the particles.
t4:1 Table IV Examples Of Nanoparticles Currently Being Evaluated For Vaccine Delivery
t4:2 Nanoparticles Description Size Vaccine Ref
t4:3 Micelles (Peptide
Cross-linked
micelles-PCMs)
PCMs are composed of block copolymers and encapsulate
immuno stimulatory DNA in the core and bind peptide
antigens through disulphide linkages. In the presence of a high
concentration of glutathione they deliver antigenic peptides
and immuno stimulatory DNA to APCs
50 nm HIV peptide vaccine (129)
t4:4 Liposomes Dimyristoyl phosphatyl-choline (DMPC):cholesterol(CH)-(7:3)
liposomes were prepared by dehydration-rehydration
followed by freezing-thawing method. The enzyme, GUS,
was successfully encapsulated and showed encouraging
activity following aerosolization
~ 6.4 μm (with 1:4
liposome:mannitol)
β-Gluc-uronidase –
enzyme (GUS)
(130)
t4:5 Polymersomes poly(g-benzyl-L-glutamate)-K (PBLG50-K) polymersomes
were prepared by the solvent removal method and influenza
hemagglutinin (HA) was surface adsorbed. When tested
in vivo, polymersomes acted as an immune adjuvant and
showed an improved immunogenicity.
250 nm influenza hemagglutinin
(HA) – subunit
vaccine
(131)
t4:6 Polymer-based Porous poly-L-lactic acid (PLA) and poly lactic-co-glycolic-acid
(PLGA) NPs were prepared by a double-emulsion-solvent
evaporation method encapsulating HBsAg and were tested
for pulmonary delivery in rat spleen homogenates.
The study demonstrated enhanced immune responses.
474–900 nm hepatitis B surface
antigen (HBsAg)
(24)
Nanocarriers Targeting Pulmonary Dendritic Cells
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463 reported that upon phagocytosis by APCs, such as DCs, these
464 NPs release the antigen intercellularly and elicit CD8+ and
465 CD4+ T cell responses (70).
466 In a study performed by Bivas-BenitaM et al., the potential of
467 enhanced immunogenicity upon pulmonary delivery of DNA
468 encapsulated in chitosan NPs was evaluated. Chitosan-DNA
469 NPs were prepared by the complexation-coacervation method
470 and the resultant DNA-loadedNPs had an average size of 376±
471 59 nm (n05), zeta-potential of 21±4 mV (n05) and a loading
472 efficiency of 99%. Pulmonary administration of the chitosan-
473 DNA NPs was shown to induce increased levels of IFN-γ
474 secretion compared to pulmonary delivery of the plasmid in
475 solution via the intramuscular immunization route. This indi-
476 cates the plausibility of achieving pulmonary delivery of DNA
477 vaccines with increased immunogenicity against tuberculosis
478 compared to immunization through intramuscular route (71).
479 The polylactides PLA and PLGA are the most broadly
480 investigated synthetic polymers in the field of drug delivery
481 (66,67,72). These are rapidly hydrolyzed upon implantation
482 into the body and are eventually removed by the citric acid
483 cycle. The hydrolyzed products form at very slow rate and
484 include lactic acid and glycolic acid which are biologically
485 compatible and easily metabolized making them safe and
486 non-toxic (66,73). However, the acidic degradation products
487 can cause problems by eliciting inflammation and also a
488 reduction in pH within the microparticles resulting in the
489 hydrolysis of the biopharmaceuticals (74).
490 Muttil et al. prepared novel NP-aggregate formulations using
491 poly(lactic-co-glycolic acid) (PLGA) and recombinant hepatitis
492 B surface antigen (rHBsAg) and showed that the dry powder
493 formulations elicited a high mucosal immune response after
494 pulmonary immunization of guinea pigs without the need for
495 adjuvants. They prepared three different formulations of dry
496 powders by spray-drying with leucine, (1) rHBsAg encapsulated
497 within PLGA/polyethylene glycol (PEG) NPs (antigen NPs,
498 AgNSD), (2) a physical mixture of rHBsAg and blank PLGA/
499 PEG NPs (antigen NP admixture (AgNASD), and (3) rHBsAg
500 encapsulated in PLGA/PEG NPs with free rHBsAg (antigen
501 NPs plus free antigen). All the particles had mass median
502 aerodynamic diameters (MMAD) of around 4.8 μm and a fine
503 particle fraction (FPF) of 50%. After immunization the highest
504 titre of serum IgG antibodies was observed in the control group
505 immunized with alum adsorbed with rHBsAg (Alum Ag) (IM
506 route) whereas the highest IgA titres were observed for animal
507 groups immunized with powder formulations via the pulmo-
508 nary route. It was also noteworthy guinea pigs immunized with
509 AgNASD dry powder exhibited IgG titers above 1,000 mIU/
510 ml in the serum (required 10 mIU/ml) suggesting the potential
511 of administering novel dry powder formulations via the pulmo-
512 nary route (75).
513 Recently a new class of biodegradable polymers, polyke-
514 tals, have been developed and are largely being investigated
515 for drug delivery purposes (76,77). This class of polymers
516have non-acidic degradation products and pH-sensitive
517ketal linkages in their backbone. These polyketals offer
518several advantages for vaccine delivery such as exhibiting
519pH-dependent hydrolysis but yet are degradable in acidic
520phagolysosomes. Polyketal copolymers degrade into bio-
521compatible small molecules minimizing inflammation com-
522pared to PLGA. An aliphatic polyketal, poly(cyclohexane-1,4-
523diyl acetone dimethylene ketal) (PCADK) degrades into ace-
524tone and 1,4-cyclohexanedimethanol which are both biocom-
525patible, and has a hydrolysis half-life of 24 days at pH 4.5 (77).
526This was later modified to a co-polyketal termed PK3 synthe-
527sized from 1,4-cyclohexanedimethanol and 1,5-pentanediol
528with a hydrolysis half-life of 1.8 days at pH 4.5 (64) making
529it much suitable for vaccine delivery.
530Heffernan MJ and Murthy N successfully prepared acid-
531sensitive polyketal NPs that released the loaded therapeutics in
532the acidic environments of tumors, inflammatory tissues and
533phagosomes. Polyketal NPs, 280–520 nm in diameter, were
534prepared by an oil-in-water (O/W) emulsion method using
535poly(1,4-phenyleneacetone dimethylene ketal) (PPADK), a
536new hydrophobic polymer that undergoes acid-catalysed hy-
537drolysis into low molecular weight hydrophilic compounds.
538(76). Heffernan et al. used polyketal PK3 to formulate a model
539vaccine that elicits CD8+ T cell responses. PK3 microparticles
540encapsulating ovalbumin (OVA), poly(inosinic acid)–poly(cyti-
541dylic acid) (poly(I:C)) - a TLR3 (Toll like receptor) agonist and a
542double-stranded RNA analog were prepared using single
543emulsion method. PK3-OVA-poly(I:C) microparticles (1–
5443 μm) at a dosage of 0.01 μg/mLwere then supplied to murine
545splenic DCs and a higher percentage of IFNγ-producing
546CD8+ T cells, TNF-α and IL-2 production in CD8+ T cells
547were observed than with DCs treated with PK3-OVA par-
548ticles or soluble OVA/poly(I:C) implying polyketal PK3
549microparticles have potential for vaccine delivery (64).
550Preparation of Polymer-Based Nanoparticles
551Different methods have been employed to synthesize polymer-
552based NPs depending on the subsequent application and type
553of drug. Polymer-based NPs can either encapsulate or surface
554adsorb the drug (68,78). Here we review some of the most
555widely used methods to prepare polymer-based NPs. Howev-
556er, a more detailed review and analysis of these methods can be
557found at Reis P et al. (78) and Avnesh K et al. (68).
558Emulsification/Solvent Evaporation and Nanoprecipitation. E-
559mulsification/solvent evaporation, also referred to as solvent
560emulsion–evaporation, involves the emulsification of an or-
561ganic polymer solution into an aqueous phase followed by
562the evaporation of the organic solvent (78). The polymer
563with or without the drug is dissolved in a volatile organic
564solvent like acetone, ethyl acetate, chloroform or dichloro-
565methane etc. and is then transferred into stirring aqueous
Kunda et al.
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566 phase with or without the presence of an emulsifier or
567 stabilizer. This emulsion is then sonicated to evaporate the
568 organic solvent and form NPs (68) (Fig. 3a). The size of the
569 resultant particles can be controlled by varying the type,
570 viscosity and amount of organic and aqueous phases, stir
571 rate and temperature (78).
572 Singh J et al. prepared diphtheria toxoid (DT) loaded
573 poly-(ε-caprolactone) (PCL) NPs via a double emulsification
574 solvent evaporation method (w/o/w) for investigating their
575 potential as a mucosal vaccine delivery system. Briefly, DT
576 was added to the internal aqueous phase containing 0.25 ml
577 10%w/v polyvinyl alcohol (PVA). The solution was emulsi-
578 fied with the organic phase comprising 100 mg of PCL in
579 5 mL of dichloromethane (DCM), using a homogenizer at
580 12,000 rpm for 2 min. The formulations were then stirred
581 magnetically at ambient temperatures and pressure for 15–
582 18 h to allow solvent evaporation and NP formation. The
583 resultant NPs were approximately 267±3 nm in size with a
584 zeta-potential of −2.6±1.2 mV. Also, the PCL NPs induced
585 DT serum specific IgG antibody responses significantly
586 higher than PLGA (79).
587 The nanoprecipitation method is a single step method
588 which is usually employed for entrapping hydrophobic drug
589 moieties. In this method, the drug and the polymer are dis-
590 solved in a water-miscible solvent, such as acetone, acetonitrile
591 or methanol (80). This organic phase is then added drop-wise
592 to an aqueous phase with or without an emulsifier/stabilizer
593 under magnetic stirring (68). NPs are formed due to rapid
594 solvent diffusion and the solvent is finally removed from the
595 emulsion under reduced pressure (81) (Fig. 3b).
596 Lee JS et al. prepared poly(ethylene glycol)-poly(ε-capro-
597 lactone) (MPEG-PCL) NPs via a nanoprecipitation method.
598 Firstly, a predetermined concentration of MPEG-PCL block
599copolymer was dissolved in 10 mL of organic solvent (ace-
600tone, acetonitrile or THF). This polymer solution was then
601added drop wise into deionized water (100 mL) under mag-
602netic stirring. The organic solvent was then evaporated under
603reduced pressure using a rotary evaporator, and the resultant
604NPs were isolated from the aqueous solution. Using different
605organic solvents and concentrations of polymer yielded NPs
606particles between ~50 to 150 nm (82).
607Emulsification and Solvent Displacement. The emulsification
608and solvent displacement method is also known as emulsifica-
609tion solvent diffusion. This method involves the precipitation
610of the polymer from an organic solution and subsequent
611diffusion of the organic solvent into an aqueous phase (78).
612The solvent that aids in the formation of emulsion must be
613miscible with water. For example, the organic polymer solu-
614tion can be added to an aqueous phase, which often contains a
615stabilizer, under strong stirring. Upon the formation of the
616emulsion (O/W), a large quantity of water is added so as to
617dilute it favoring the diffusion of additional organic solvent
618from the dispersed droplets. This process leads to the precip-
619itation of the polymer (81). An interfacial turbulence is created
620between the two phases as the solvent diffuses resulting in the
621formation of smaller particles and is believed that as the water-
622miscible solvent concentration increases the NPs tend to ac-
623quire a smaller size (80) (Fig. 3c).
624Ranjan AP et al. have recently prepared biodegradable
625NPs containing indocynanine green (ICG) using chitosan
626modified poly(L-lactide-co-epsilon-caprolactone) (PLCL):
627poloxamer (Pluronic F68) blended polymer by an emulsifi-
628cation solvent diffusion technique. PVA and chitosan were
629used as stabilizers in the process of making the NPs. The
630average particle size of the resultant NPs was between 146±
Fig. 3 Schematic representation of a emulsification/solvent evaporation technique, b emulsification and solvent displacement technique, c salting-out
technique and d nanoprecipitation technique.
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631 3.7 to 260±4.5 nm and the zeta potential progressively
632 increased from −41.6 to +25.3 mV with increasing amounts
633 of chitosan (83).
634 Salting Out. The salting out method is based on the separation
635 of a water-miscible organic phase from an aqueous solution by
636 adding salting out agents (78,80,84). Briefly, the polymer is
637 dissolved in a water-miscible organic solvent such as acetone
638 or tetrahydrofuran (THF) which is then added under strong
639 stirring to an aqueous solution containing salting out agents
640 (for example magnesium chloride, calcium chloride) and an
641 emulsifier or stabilizer to form an O/W emulsion (80,81,85).
642 This O/W emulsion is diluted by adding a large volume of
643 water under mild stirring thus reducing the salt concentration/
644 ionic strength and favouring the movement of the water-
645 miscible organic solvent into the aqueous phase. This process
646 leads to the formation of nanospheres and as a final step the
647 NPs formed are freed from the salting out agents either by
648 centrifugation or cross-flow filtration (80) (Fig.3d).
649 Konnan YN et al. prepared sub-200 nm NPs using a
650 salting out method. Typically, a solution of PLGA and
651 PLA in THF was added under mechanical stirring to an
652 aqueous phase containing PVA and magnesium chloride
653 hexahydrate (MgCl2.6H2O) as a salting out agent forming
654 an O/W emulsion. To this, a large volume of water was
655 added favoring migration of the water-miscible organic
656 solvent into the aqueous phase forming NPs which were
657 later purified by cross flow filtration (86).
658 Table V lists some of the advantages and disadvantages
659 of nanoparticle preparation methods (77).
660
661 Encapsulation or Adsorption
662 A high loading capacity is one of the most desired qualities of
663 NP-based vaccines. The main advantage of having a high
664 loading capacity is that the amount of polymer required to
665 carry the drug/vaccine is reduced (81) hence minimizing any
666 toxic effects from the polymer. Drugs/vaccines can be loaded
667 into or onto NPs using two approaches (Fig. 4) (87). The first is
668 encapsulation where the drug/vaccine is incorporated into the
669NP at the time of preparation; the second is adsorption where
670the drug/vaccine is either chemically or physically adsorbed
671onto the NP after preparation.
672It is important to note that the chemical structure of the
673drug/vaccine, the polymer and the conditions of drug loading
674influence the amount of drug/vaccine bound to the NPs and
675the type of interactions that occur between them (81). In addi-
676tion, the encapsulation or adsorption of a drug/vaccine depends
677on the disease to be treated or prevented, route of administra-
678tion, manufacturing feasibility and economic challenges.
679Bivas-Benita M et al. prepared PLGA–polyethyleneimine
680(PEI) NPs by an interfacial deposition (88) method. The
681resultant NPs were loaded with Mycobacterium tuberculosis
682(Mtb) Antigen 85B (Ag85B) by adding the NP suspension to
68325 μg/mL DNA plasmid solution. The characterization stud-
684ies revealed that the particle size increased from 235 to
685275 nmwhen resuspended in water and 271 nm in saline with
686the mean zeta potential increase from+38.8mV to +40.6mV
687respectively. TheNPs greatly stimulated humanDCs resulting
688in the secretion of IL-12 and TNF-α at comparable levels to
689that observed after stimulation using lipopolysaccharide
690(LPS) (89).
691Biodegradable polymer-based NPs have been widely ex-
692plored and appear to be well tolerated when administered into
693the body. These NPs have gained significant attention and are
694being accepted as effective delivery systems with the develop-
695ment of NP based vaccines (90,91). In addition, the NP based
696vaccines need to be formulated appropriately, as dry powders
697and at low cost to help achieve effective mass vaccination.
698Adjuvants
699Modern day vaccines contain pure recombinant or synthetic
700antigens that are less immunogenic than live or killed whole
701organism vaccines. Thus, in order to obtain a strong im-
702mune response upon administration of antigen and provide
703long term protection against the infection, adjuvants are
704included within the formulation (92). Adjuvants are substan-
705ces used in combination with an antigen to produce a
706stronger and more robust immune response than the anti-
707gen alone (93). Adjuvants also provide a depot for the
t5:1 Table V Advantages and Disadvantages of Nanoparticle Preparation Methods
t5:2 Method Advantages Disadvantages
t5:3 Emulsification/Solvent Evaporation Hydrophilic and hydrophobic drugs can be
encapsulated
Agglomeration of nanodroplets during evaporation
t5:4 Emulsification and Solvent
Displacement
Control over the size of nanoparticles Possibility of water-soluble drug leaking into the external
aqueous phase, Large amounts of water to be removed
t5:5 Salting Out High loading efficiency, Easy scale-up Removal of electrolytes, Incompatibility of salting-out agents
with drugs
t5:6 Nanoprecipitation Simple, fast and reproducible, Easy scale-up,
Low surfactant concentrations required
Less polymer in the organic phase
Kunda et al.
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708 antigen favoring a slow release, reduce the dose of antigen
709 required to generate a strong immune response, modulate
710 the immune response, aid in targeting the APCs, and pro-
711 vide danger signals helping the immune system respond to
712 the antigen (92–94). The selection of an adjuvant depends
713 on the antigen, delivery system, route of administration and
714 possible side-effects. However, an ideal adjuvant should
715 have a long shelf life and be safe, stable, biodegradable,
716 economical and should not induce an immune response
717 against themselves (92).
718 Despite massive efforts over nearly 90 years into the
719 research and development of adjuvants, the list of adjuvants
720 that are clinically approved is short. The prime reason being
721 their safety coupled with limited data on the predictability of
722 safety using available animal models (95). The serious ad-
723 verse events in the recent clinical trials of Merck’s (96) and
724 Novartis’s (NCT00369031) (97) HIV vaccines using
725 adenovirus- and toxin-based adjuvanted delivery systems
726 has moved the research into further investigations in devel-
727 oping nutritive adjuvanted delivery systems (Vitamins A, C,
728 D, E, flavonoids and plant oils). These may prove safer in
729 clinical trials (98,99). Table VI lists adjuvants in development
730 or licensed for human use.
731 Alum salts have a well-established safety record, are the
732 most widely used human adjuvants and are used as standards
733 to assess other adjuvants (92,93,95,100). Despite their wide
734 use their mechanism is poorly understood and thus rarely
735 induce human responses (92).
736 Wee JLK et al. used a sheep animal model to evaluate the
737 delivery of ISCOMATRIX adjuvanted influenza vaccine via
738 its mucosal site of infection for improved vaccine effectiveness.
739 Upon pulmonary immunization with low antigen doses
740 (0.04 μg) of adjuvanted influenza equivalent serum antibody
741 levels were induced when compared to an almost 375-fold
742 higher dose (15 μg) unadjuvanted influenza delivered subcu-
743 taneously suggesting the successful use of this combination for
744 improved protection (101).
745DRY POWDER PREPARATION TECHNIQUES
746The use of liquid suspensions of NPs are often accompanied by
747several disadvantages such as particle aggregation and sedi-
748mentation leading to physico-chemical instability, reduced or
749loss of biological activity of the drug, contamination, and
750hydrolysis leading to degradation of the polymer (102). To
751overcome these problems, preparations can be stored and
752transported in a dry form (102). In addition, for vaccines, the
753delivery of a dry powder by inhalation has the potential benefits
754of a) increased stability during transport and administration, b)
755increased safety by eliminating contamination risks and c)
756improved cost-effectiveness (103). The most commonly used
757methods for transforming liquid preparations into dry powders
758are freeze-drying, spray-drying, spray-freeze-drying and the
759use of super critical fluid technologies. Each of these methods
760has advantages and disadvantages and are selected depending
761on the desired attributes such as narrow particle size
Fig. 4 The molecule of interest
(DNA/Drug/Peptide/Protein)
is either encapsulated (Left) within
or surface adsorbed (Right) onto
the polymer-based nanoparticle.
t6:1Table VI List of Adjuvants in Either Development, Testing or for
Human Use
t6:2Category Examples
t6:3Mineral Salts Aluminium hydroxide (Alum)
t6:4Potassium aluminium sulphate
t6:5Aluminium phosphate
t6:6Oil emulsions MF59
t6:7Particulate adjuvants Virosomes
t6:8ISCOMS (Immuno stimulating complexes)
t6:9Microbial derivatives Monophosphoryl lipid A-MPL(TM)
t6:10Plant derivatives QS-21 (Saponin)
t6:11ADVAX
t6:12Miscellaneous AS04 (liposome formulation containing MPLA
& QS-21), polymeric adjuvants,
CpG oligodeoxynucleotides, vitamins
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762 distribution, improved bioavailability, enhanced stability, im-
763 proved dispersibility and controlled release (104,105).
764 Freeze-Drying
765 Freeze-drying, also known as lyophilisation, is commonly used
766 in industry to ensure long term stability and preservation of the
767 original properties of various biological products such as viruses,
768 vaccines, proteins, peptides and their carriers; NPs and lip-
769 osomes (102,106). This process comprises of removing water
770 from a frozen sample by sublimation and desorption under
771 vacuum (106) and can be divided into three steps: freezing
772 (solidification), primary drying (ice sublimation) and secondary
773 drying (desorption of unfrozen water) (102). However, this
774 process is relatively slow, very expensive and generates various
775 stresses on the biological product during both the freezing and
776 drying steps (106). Protectants in the form of excipients are
777 usually added to stabilize the products, avoid aggregation and
778 to ensure acceptable tonicity and reconstitution (106,107). Sug-
779 ars such as glucose, sucrose, trehalose,mannitol, lactose, dextran
780 ormaltose with or without surfactants such as poly(vinyl) alcohol
781 or poloxamer 188 are often employed as protectants to stabilize
782 the product and prevent coalescence (107,108). The concentra-
783 tion and the NP/sugar mass ratio also play an important role in
784 determining the stability and long term storage of the final
785 product (102). AnhornMG et al. evaluated the effect of different
786 concentrations of sucrose, mannitol and trehalose as cryopro-
787 tectants on the physico-chemical characteristics of resulting NPs
788 by analyzing the appearance, particle-size and polydispersity
789 index (107). Long term stability studies indicated that the ab-
790 sence of cryoprotectants led to particle growth whereas their
791 presence reduced aggregation. Particles freeze-dried with su-
792 crose and trehalose at 2% and 3%w/v had more controlled
793 particle size and these sugars appeared to be superior to man-
794 nitol at similar concentrations (107).
795 Spray-Drying
796 Spray-drying is a one-step preparation of dry powders. It is a
797 process that converts liquid feed (solution, suspension or col-
798 loidal dispersion) into dry particles (109). The process can be
799 divided into four parts (110): atomization (1), spray-air contact
800 (2), drying (3) and separation (4). The liquid feed is atomized
801 (1) to break the liquid into droplets and this spray form comes
802 into contact with a hot gas (2), causing rapid evaporation of
803 the droplets to form dry particles (3). The dry particles are
804 then separated from the hot gas with the help of a cyclone (4)
805 (105). Compared to particles obtained from micronization
806 using milling, spray-dried particles are more spherical and
807 have a homogenous size-distribution resulting in a higher
808 respirable fraction which is advantageous for pulmonary de-
809 livery (105). In addition, spray-drying has the advantage of
810 being; simple, easily scalable, cost-effective, suitable for heat-
811sensitive products and enables high drug loading (110). An
812economically acceptable yield can now be achieved with the
813fourth and newest generation of laboratory-scale spray dryer
814developed by Büchi, the Nano Spray Dryer B-90. This nano
815spray dryer can generate particles of size ranging from 300 nm
816to 5 μm for milligram sample quantities at high yields (up to
81790%) (111). However, there is a chance of degradation of
818macromolecules during the process due to high shear stress
819in the nozzle and thermal stress while drying (105). Fourie PB
820et al. (21) describes the challenges such as thermal stress,
821osmotic stress, and scalability involved with spray-drying of
822vaccines. Fourie PB et al. formulated a dry powder TB vaccine
823for delivery to the lung by preparingMycobacterium bovis Bacillus
824Calmette–Guérin (BCG) spray-dried particles which, when
825administered into M. tuberculosis infected guinea-pigs, resulted
826in enhanced immunogenicity levels compared to an equal dose
827injected subcutaneously into control animals (21).
828Spray-Freeze Drying
829Spray-freeze drying (SFD) is a drying process that usually
830involves atomization, rapid freezing and lyophilisation (112).
831A solution containing the drug is sprayed into a vessel that
832contains a cryogenic liquid such as nitrogen, oxygen or argon.
833As the boiling temperatures of these cryogenic liquids are very
834low they cause the droplets to freeze instantly. The resulting
835droplets are then collected and lyophilized to obtain porous dry
836powder particles suitable for respiration (105). The advantage
837of SFD is the ability to produce particles with adjustable sizes
838(112) and as it is conducted at sub-ambient temperature, ther-
839molabile polymers and highly potent biopharmaceuticals can
840be formulated into dry powder products (105). However, the
841major disadvantage of this technique is the stresses associated
842with freezing and drying, which may cause irreversible damage
843to proteins (113). This is displayed as structural denaturation,
844aggregation and loss of biological activity upon rehydration
845(105). In addition, loss of stability due to unfolding and aggre-
846gation remains amajor challenge (113) and also themethod has
847low process efficacy, is time consuming, and expensive (114).
848Amorij J-P et al. showed that an influenza subunit vaccine
849powder prepared by SFD using oligosaccharide inulin as a
850stabilizer and delivered via the pulmonary route to BALB/c
851mice induced systemic humoral (IgG), cell-mediated (Il-4,
852IFN-γ) and mucosal immune responses (IgA, IgG). Whereas
853vaccination with a liquid subunit vaccine via either pulmonary
854or intramuscular route induced only systemic humoral (IgG)
855immune responses suggesting that powder vaccine formula-
856tions could be beneficial for immunization (23).
857Supercritical Fluid Technology
858Supercritical fluids (SCF) are compressed gases or liquids above
859their critical temperatures (Tc) and pressures (Pc), and possess
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860 several advantages of both gases and liquids (105). The density
861 and thus solvating power can be controlled by varying the
862 temperature and pressure. SCF can be prepared using carbon
863 dioxide (CO2), water, propane, acetone, nitrous oxide (N2O),
864 trifluoromethane, chlorodifluoromethane, diethyl ether, water,
865 or CO2 with ethanol (114). However, because of its accessible
866 critical point at 31°C and 74 bar, its low cost and non-toxicity,
867 CO2 is the most widely used solvent in SCF. In addition, its
868 low critical temperaturemakes supercritical (SC) CO2 suitable
869 for handling heat-labile solutes at conditions close to room
870 temperature. Therefore, SC CO2 has potential as an alterna-
871 tive to conventional organic solvents for use in solvent-based
872 processes for forming solid dosage forms (105).
873 There are two major principles for particle precipitation
874 with supercritical fluids. One employs SCF as a solvent and
875 the other as an antisolvent (115). In the first, the drug is
876 dissolved in the SCF followed by sudden decompression, after
877 which the solution is passed through an orifice and rapidly
878 expanded at low pressure. Rapid Expansion of a Supercritical
879 Solution (RESS) employs this principle (114). In the second
880 process, the solute is insoluble in SCF and hence utilizes SCF
881 as an antisolvent. A solute is dissolved in an organic solvent
882 and then precipitated by the SCF (antisolvent). Precipitation
883 occurs when the SCF is absorbed by the organic solvent
884 followed by expansion of the liquid phase and a decrease in
885 the solvation power leading to particle formation. The Gas
886 Anti-Solvent (GAS), Aerosol Solvent Extraction System
887 (ASES), Supercritical Fluid Antisolvent (SAS), Precipitation
888 with Compressed Antisolvent (PCA), Solution Enhanced Dis-
889 persion by Supercritical Fluids (SEDS), and supercritical fluid
890 extraction of emulsion (SFEE) are the processes that employ
891 this second principle (114). Using these techniques particles
892 can be formed in a well-ordered fashion to achieve the desired
893 morphology and any negative effects on the macromolecules
894 can be minimized (105,113). Thorough discussions of these
895 techniques including their advantages and disadvantages have
896been recently published by Al-fagih I et al. (114) and elsewhere
897(105,113,115–118).
898The fine powders produced via SCF precipitation are often
899less charged than those produced mechanically allowing them
900to flow more freely and thus to be more easily dispersed from a
901DPI. In addition, SCF processes allow the production of inhal-
902able particles that are more uniform in terms of crystallinity,
903morphology, particle-size distribution and shape than those
904produced via jet milling. In spite of its potential, SCF is still
905classified as an emerging technology that is still to be exploited
906in DPI products; with concerns being raised over the potential
907denaturing effects of the solvents/antisolvents used in this pro-
908cess (105). Amidi M et al. prepared diphtheria toxoid (DT)
909containing microparticles using a supercritical fluid (SCF)
910spraying process and obtained dry powder microparticles with
911a median volume diameter between 2 and 3 μm. Pulmonary
912immunization of guinea pigs with DT-TMC (N-Trimethyl
913chitosan) microparticles resulted in a strong immunological
914response as reflected by the induction of IgM, IgG, IgG1 and
915IgG2 antibodies comparable to or significantly higher than
916those achieved after subcutaneous (SC) administration of
917alum-adsorbed DT demonstrating an effective new delivery
918system for pulmonary administered DT antigen (119).
919Table VII highlights some recent studies that have
920employed various dry powder preparation techniques and
921the subsequent evaluation for vaccine delivery.
922CONCLUSION
923Pulmonary administration has gained significant attention
924in the recent years as a potential non-invasive route for
925vaccines, and has also shown great promise as an effective
926means of vaccination. Much of the success is due to the
927lung’s large surface area (80 sq. m), and rich blood supply
928leading to rapid absorption coupled with an abundance of
t7:1 Table VII Recent studies on dry powder particle-based vaccine delivery
t7:2 Disease Antigen Carrier/Stabilizer Dry Powder Preparation Size (μm) Model Ref
t7:3 Bacterial Infections Bacteriophages Trehalose, Leucine SD 2.5–2.8 NA (132)
t7:4 Diptheria Diptheria Toxoid Chitosan SCF 3–4 GP (119)
t7:5 Diptheria Diphtheria CRM-197 antigen L-leucine SD ~ 5 GP (32)
t7:6 Hepatitis B Recombinant hepatitis B
surface antigen (rHBsAg)
Leucine SD 4.8 GP (75)
t7:7 Influenza Influenza monovalent Inulin SD, SFD 2.6 (SD), 10.5 SFD) M (133)
t7:8 Influenza Influenza subunit Inulin SFD ~ 10 M (23)
t7:9 Tuberculosis Ad35-vectored tuberculosis
(TB) AERAS-402
Mannitol-cyclodextrin-
trehalose-dextran, MCTD
SD 3.2–3.5 NA (134)
t7:10 Tuberculosis Bacille Calmette-Guerin (BCG) Leucine SD 2–3 GP (135)
t7:11 Tuberculosis Recombinant antigen
85B (rAg85B)
NA SD 2.8 GP (136)
SD Spray drying, SFD Spray-freeze drying, SCF Supercritical Fluid; M Mice, GP Guinea Pigs; NA Not Available
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929 local APCs that present antigen in a way to induce both
930 mucosal and systemic immune response. Recent progress in
931 targeting vaccines specifically to DCs for an enhanced im-
932 mune response with low doses has paved way for developing
933 new vaccine technology. Polymer-based NPs offer the ad-
934 vantage of biodegradabiltiy, avoiding antigen degradation if
935 encapsulated and through chemical attachments can target
936 DCs. However, more research is needed to understand the
937 fate of NPs after inhalation, their interaction with the biolog-
938 ical cells and their toxicity (nanotoxicity). The method of
939 formulation of NP based vaccines into dry powders is of equal
940 importance as it provides the opportunity to maintain the
941 stability and integrity of the antigen, ease of transport and
942 administration. The right combination of polymer chemistry,
943 polymer-based NPs, immunology, dry powder technology,
944 delivery device and animal models will lead to the discovery
945 of next generation of vaccine delivery systems.
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